I

n an unprecedented move, the Food and Drug Administration rescinded a recent decision that an Alkermes (ALKS) drug being developed for treating depression would not be reviewed. And the sudden reversal is raising questions about the extent to which the agency is willing to become more flexible about drug approvals in an overheated political climate focused on access to medicines.

Here’s the backstory: On April 2, the company unexpectedly disclosed that the FDA issued a so-called refuse-to-file letter, which meant the marketing application for its drug would not be reviewed. Why? There was “insufficient evidence of overall effectiveness” in treatment-resistant depression, and the agency wanted additional “well-controlled clinical trials.”

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.